Targeting Epigenetic Regulation for Cancer Therapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 1537
Special Issue Editors
Interests: cancer; gene expression; phytochemicals; molecular genetics; epidemiology
Special Issues, Collections and Topics in MDPI journals
Interests: gastrointestinal cancers; phytotherapeutics; microbial and molecular genetics; pyhtochemistry; epidemiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Epigenetics has emerged as a critical area of study in recent decades, revealing how heritable changes in gene expression occur without altering the DNA sequence. DNA methylation, initially the most studied epigenetic mechanism, has now been complemented by a broader understanding of histone modifications, chromatin remodeling, and non-coding RNAs.
This Special Issue aims to explore the complex network of epigenetic factors beyond DNA methyltransferases (DNMTs) that regulate gene activity, genome stability, and cellular identity. We welcome contributions from a broad range of biological systems and disciplines that address how different epigenetic mechanisms function, interact, and contribute to physiological or pathological processes, with a particular emphasis on their implications for cancer biology and therapy. Understanding how epigenetic alterations drive tumor progression, resistance, and immune evasion may offer promising avenues for developing more precise and effective cancer treatments.
Recent advances in epigenomic technologies, such as ChIP-seq, ATAC-seq, and single-cell epigenomics, are rapidly expanding our understanding of chromatin states and gene regulatory networks. This issue will feature research that uncovers novel epigenetic regulators, their mechanisms of action, and their potential as therapeutic targets—especially in cancer, where epigenetic interventions are increasingly being investigated as part of combination therapies or as standalone approaches. Studies elucidating the epigenetic basis of therapy resistance, tumor heterogeneity, or immune modulation are particularly welcome.
We invite original research articles, reviews, and perspective papers that investigate epigenetic mechanisms beyond DNMTs, including histone-modifying enzymes, chromatin remodelers, and non-coding RNAs. Both experimental and computational studies are encouraged, as well as work spanning molecular, cellular, organismal, or environmental levels. Submissions that explore translational aspects—such as epigenetic biomarkers or the development of epigenetic drugs for cancer therapy—are of particular interest. All topics related to the central theme of epigenetic regulation—including novel insights, emerging technologies, comparative analyses, and interdisciplinary approaches—are welcome.
Dr. Bence Raposa
Dr. John M. Macharia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- chromatin remodeling
- histone modifications
- non-coding RNAs
- gene regulation
- cancer therapy
- epigenetic biomarkers
- therapeutic targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
